Knockdown of PAX3-FOXO1 was selected against tumor cells in the absence of puromycin selection that could not be maintained in vivo, so we used this experimental design to benchmark the fitness of cells that may have slowly increasing PAX3-FOXO1 expression over time against the parental cell line. This evidence concerns the gene FOXO1 and neoplasm.